替罗非班治疗急性冠脉综合征的临床研究  

Clinical Investigation of Tirofiban in Treatment of Acute Coronary Syndrome

作　　者：李芳[1] 王琳[1] 卜军[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院,武汉430030

出　　处：《内科急危重症杂志》2004年第2期72-74,86,共4页Journal of Critical Care In Internal Medicine

摘　　要：目的 :本研究旨在评价替罗非班用于治疗中国人急性冠脉综合征的有效性和安全性。方法 :78例急性冠脉综合征患者按就诊顺序随机、双盲分配为受试组 (替罗非班 +肝素 )和对照组(安慰剂 +肝素 ) ,疗程 2～ 4 .5d。终点事件是 4 .5d和 30d的复合缺血事件 (死亡、新的心梗、顽固性心肌缺血 )。结果 :4 .5d复合终点事件发生率受试组低于对照组 (0 %vs 5 .2 6 % ,P =0 .117)。30d复合终点事件发生率受试组亦明显低于对照组 (0 %vs 2 1.0 5 % ,P =0 .0 83)。出血并发症在受试组比对照组有增多趋势 (2 0 .5 %vs 5 .13% ,P =2 .86 8)。结论 :替罗非班在急性冠脉综合征标准治疗基础上能进一步减少缺血事件发生率 。Objective: To evaluate the efficacy and safety of tirofiban in treatment of acute coronary syndrome (ACS) among Chinese people. Methods:Seventy-eight patients were randomly assigned in a double-blind manner to receive tirofiban plus heparin or placebo plus heparin alone for 2- 4.5 days. The composite end point events consisted of death, myocardial infarction, or refractory ischemia within 4.5 days and 30 days after randomization. Results:The frequency of the composite primary end point events at 4.5 days was lower among the patients who received tirofiban plus heparin than those who received heparin plus placebo (0% vs 5.26%, P= 0.117). The occurence rates of the composite end point events in tirofiban plus heparin group were obviously lower than those in the heparin group at 30 days (0% vs 21.05%, P= 0.083). Bleeding occurred in 20.5% of the patients receiving tirofiban plus heparin and 5.13% of the patients receiving heparin alone. Conclusion: Tirofiban may further lower the incidence of ischemic events safely in patients with acute coronary syndrome on the basis of standard treatments in ACS.

关 键 词：急性冠脉综合征 GPIIb/Ⅲa受体拮抗剂 替罗非班 有效性 安全性 

分 类 号：R543.3[医药卫生—心血管疾病]